Table 2. Summary of phase III studies of targeted therapies for treatment of HCC.

Study and population	Comparators	Median OS
REFLECT: Advanced HCC with no previous systemic treatment (116)	Lenvatinib vs. sorafenib	Lenvatinib: 13.6 months; Sorafenib: 12.3 months; (HR 0.92; 95% CI: 0.79–1.06; non-inferiority criteria met)
CELESTIAL: Advanced HCC, previously treated with sorafenib (113)	Cabozantinib vs. placebo	Cabozantinib: 10.2 months; Placebo: 8.0 months; (HR 0.76; 95% CI: 0.63–0.92; P=0.005)
REACH-2: Advanced HCC, previously treated with sorafenib and AFP ≥400 ng/mL (118)	Ramucirumab vs. placebo	Ramucirumab: 8.5 months; Placebo: 7.3 months; (HR 0.710; 95% CI: 0.531–0.949; P=0.0199)
RESORCE: Advanced HCC, previously treated with sorafenib (114)	Regorafenib vs. placebo	Regorafenib: 10.6 months; Placebo: 7.8 months; (HR 0.63; 95% CI: 0.50–0.79; P<0.0001)
SHARP: Advanced HCC with no previous systemic treatment (117)	Sorafenib vs. placebo	Sorafenib: 10.7; Placebo; 7.9 months; (HR 0.69; 95% CI: 0.55–0.87; P<0.001)
IMBrave150: Advanced HCC with no previous systemic treatment (115)	Atezolizumab plus bevacizumab vs. sorafenib	Atezolizumab plus bevacizumab: 19.2 months; Sorafenib: 13.4 months; (HR 0.66; 95% CI: 0.52–0.85; P=0.0009)

HCC, hepatocellular carcinoma; OS, overall survival; AFP, α-fetoprotein; CI, confidence interval; HR, hazard ratio.